In Australia, collaborative research efforts, bipartisan political will and subsidised medication costs have allowed around 13 000 people to be maintained on antiretroviral therapy. Despite this, the challenges of continuous lifelong suppressive therapy remain, as currently there is no cure.
Poor adherence can lead to disease progression and drug resistance, limiting future treatment options. Antiretroviral resistance in Australia appears to have been stable, but changing epidemiology and evolving viral subtypes may impact these rates. This article will reflect on the advances in antiretroviral research, rollout and resistance in our region.
Australia has benefitted from early access and rollout of ART, and now has one of the highest treatment rates in the world, with around 50-70% of those diagnosed receiving treatment, and 85-95% of these with a suppressed viral load (see Figure 1 in PI resistance 11 . In Victoria and NSW, rates of transmitted drug resistance have since remained stable at 10-16% when last analysed [11] [12] [13] . Since then, there appear to be some shifts in the epidemiology of HIV in South Australia, which comprises 4% of the national HIV burden, with an increased incidence of non-B subtypes now accounting for almost half of new diagnoses 14 . They tend to occur in females born overseas, acquired overseas through heterosexual transmission, and reflect increasing migration from high prevalence countries 15, 16 . In Focus Renewed political will, financial commitment and innovative solutions are needed to bridge this gap.
